HOTH THERAPEUTICS ANNOUNCES GROUNDBREAKING POSITIVE RESULTS: HOTH'S HT-VA GDNF SURPASSES SEMAGLUTIDE IN WEIGHT LOSS, GLUCOSE CONTROL, AND LIVER HEALTH IN OBESITY MODEL
HOTH THERAPEUTICS INC - GDNF REDUCES LIVER WEIGHT BY 20-30%
HOTH THERAPEUTICS INC - GDNF ATTENUATES WEIGHT GAIN BY 10-15% LEADING TO A PLATEAU IN THE FINAL WEEKS OF TREATMENT
Source text: ID:nPn4Cl3D6a
Further company coverage: HOTH.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.